The Service Line

CMS just published the audit playbook every state will use on the fastest-growing benefit in behavioral health, and the growth curve behind it explains why. The Centers for Medicare and Medicaid Services (CMS) released a 173-page toolkit on August 5, 2026 to help state Medicaid and Children’s Health Insurance Program (CHIP) agencies tighten oversight of Applied Behavior Analysis (ABA), the therapy billed for autism treatment. National Medicaid and CHIP spending on ABA rose from roughly $2 billion in 2021 to $10 billion in 2025, a 400 percent increase, while the number of diagnosed children actually receiving services grew just 67 percent over the same span; median annual spending per child rose from $8,903 to $21,203. The toolkit recommends states require prior authorization above certain weekly-hour thresholds, cap billing before mandating therapeutic breaks, tighten documentation review, and flag 40-hour-a-week treatment plans as, in CMS’s words, not a best practice. “We were seeing quite an explosion in costs,” CMS senior Medicaid policy official Caprice Knapp said. “We want to make sure the profit motivation isn’t overtaking what’s in the best interest of children.” It is not a new federal mandate; adoption is up to each state. Confidence: High. Source: CMS Launches New State Toolkit to Protect Children with Autism, CMS.

Reimbursement

Behavioral health’s facility side got a modest raise from Medicare this week. Its Medicaid outpatient side got squeezed by an actual state budget vote. CMS finalized the Fiscal Year (FY) 2027 Inpatient Psychiatric Facility (IPF) Prospective Payment System rule on July 31, 2026, a 2.2 percent net payment increase that raises the federal per diem base rate from $892.87 to $912.40 and the electroconvulsive therapy payment from $673.85 to $688.59. The rule also raises the cost outlier threshold 3.5 percent, to $40,750, and caps total outlier payments at 20 percent of a facility’s total IPF payments, with an exemption for facilities running fewer than 50 annual stays. The same week, Colorado’s Department of Health Care Policy and Financing cut most Medicaid provider rates 2 percent effective July 1, 2026, on top of an April 1 rate alignment that pegged fee-for-service payments to 85 percent of 2025 Medicare rates, and moved its Comprehensive Safety Net Providers, the backbone of the state’s community behavioral health system, onto a bundled prospective-payment rate covering nine required services. Confidence: High on both rules’ terms; Medium on how the bundled rate nets out for any individual Colorado clinic. Sources: FY 2027 IPF PPS Final Rule, CMS, July 2026 Provider Bulletin, Colorado Department of Health Care Policy and Financing.

Enforcement

Kentucky’s largest addiction treatment network just became a $16.2 million lesson in what happens when whistleblowers count credentials. A federal judge in the Eastern District of Kentucky approved a $16,205,774.05 civil judgment against Addiction Recovery Care (ARC) and affiliates Pioneer Health Group and Science Hill Family Care on July 28, 2026, unsealing a False Claims Act suit that three former ARC employees, a billing supervisor and two peer support specialists, filed under seal in April 2023. The government alleged that between January 2018 and March 2024, ARC billed psychotherapy, psychiatric evaluations, and mental health assessments as though performed by higher-licensed clinicians than the non-clinicians who actually delivered them, and billed individual therapy codes for sessions that were actually group therapy. An earlier unsigned draft had put the judgment at $27.7 million before it was reduced for ARC’s financial condition; the settlement resolves allegations only, with no determination of liability. Confidence: High on the settlement terms; the underlying allegations remain unproven. Source: Addiction Recovery Care and Affiliates Agree to Pay $16.2 Million Civil Judgment, Department of Justice.

Who’s Buying

A private equity firm just exited a behavioral health platform onto the municipal bond market instead of selling to a strategic buyer or another sponsor. Clearview Capital agreed on July 29, 2026 to sell Advantage Behavioral Health (ABH), a New Jersey-based network of more than 30 mental health and sober-living facilities across eight states expected to treat over 500,000 patients annually, to QCF/I, a nonprofit built by former municipal bond banker James Golden that has been assembling behavioral health assets since 2024. The deal runs through a non-rated $610 million municipal bond issuance underwritten by KeyBanc Capital Markets, delivering roughly $415 million upfront to Clearview and ABH’s founders and management, with up to $100 million more contingent on hitting performance targets against a projected 2026 EBITDA near $78 million; Clearview had recapitalized ABH barely a year earlier, in April 2025. KeyBanc is reportedly advising on close to a dozen similar nonprofit, bond-financed conversions worth roughly $3 billion combined, a sign that tax-exempt financing is becoming a standing exit ramp for behavioral health platforms rather than a one-off. Confidence: Medium; terms are as reported by financial press and have not been independently verified against bond-offering filings. Source: Private Equity Firm Sells Mental Health Chain to Municipal Bond Market, Bloomberg.

Clinical Policy

The buprenorphine telehealth rule most operators built their opioid-treatment staffing model on is permanent. The broader prescribing flexibility it sits inside is not, and the clock resets again in five months. The Drug Enforcement Administration (DEA) and the Department of Health and Human Services’ January 2025 final rule permanently allows clinicians to prescribe buprenorphine for opioid use disorder via telemedicine, including to new patients never seen in person, for an initial six-month period. But the broader Schedule II through V telemedicine prescribing flexibilities that most virtual psychiatry and stimulant-prescribing practices also rely on remain temporary: DEA’s fourth extension, issued December 31, 2025, runs only through December 31, 2026, and the agency has not published the permanent regulations it has promised since 2023. Any group whose virtual psychiatry or opioid use disorder model depends on prescribing controlled substances without an in-person visit should treat December 31, 2026 as a real deadline until DEA says otherwise. Confidence: High on the buprenorphine rule’s permanence and the extension’s end date; Medium on whether DEA meets its own year-end timeline again. Sources: DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care, Drug Enforcement Administration, DEA and HHS Issue Final Telemedicine Rule for Buprenorphine Access, Substance Abuse and Mental Health Services Administration.

The Operator Metric

400 percent versus 67 percent. That is the gap between how fast Medicaid’s autism therapy spending grew and how fast the population receiving it grew, over the same four years. CMS’s new ABA toolkit puts national Medicaid and CHIP ABA spending at about $2 billion in 2021 and $10 billion in 2025, while the number of diagnosed children actually receiving services rose only 67 percent in that window; median annual spending per child climbed from $8,903 to $21,203. That divergence, cost growing roughly six times faster than caseload, is the number every ABA operator should be able to explain about their own book of business before a state program-integrity unit asks. The toolkit specifically flags treatment plans above 16 hours a week for special review and calls 40-hour-a-week treatment “not a best practice,” a bar worth checking your own utilization against now rather than after an audit letter arrives. Confidence: High on the reported figures. Source: CMS Launches New State Toolkit to Protect Children with Autism, CMS.